Article
An FDA inspection raises questions about Bristol Myers Squibb's liso-cel facility and the CVR, but
Rating:
0.0
Views:
78
Likes:
1
Library:
1
For months, speculation over Bristol Myers Squibb and its $9 Celgene CVR has focused on whether the FDA would be able to inspect the Big Pharma's cell therapy plant in Texas in time to approve their 'liso-cel' cancer therapy. But on Friday, the agency posted a document to its website
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value